# Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma

> **NCT03370718** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 18 (actual)

## Conditions studied

- Metastatic Carcinoma in the Adrenal Cortex
- Stage III Adrenal Cortex Carcinoma AJCC v8
- Stage IV Adrenal Cortex Carcinoma AJCC v8
- Unresectable Adrenal Cortex Carcinoma

## Interventions

- **DRUG:** Cabozantinib
- **OTHER:** Pharmacogenomic Study
- **OTHER:** Pharmacokinetic Study

## Key facts

- **NCT ID:** NCT03370718
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-26
- **Primary completion:** 2024-01-12
- **Final completion:** 2024-01-12
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2024-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03370718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03370718, "Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03370718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*